Lv3
368 积分 2023-06-12 加入
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
1天前
待确认
The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
1天前
已完结
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
2天前
已完结
BCL6 confers resistance to HDAC inhibitors in DLBCL
2天前
已完结
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?
2天前
已完结
PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer
3天前
已完结
Paradigm shift: combination BET and JAK inhibition in myelofibrosis
7天前
已完结
Fedratinib in 2025 and Beyond: Indications and Future Applications
9天前
已完结
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors
29天前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
